¿Metformin to Treat Abdominal Aortic Aneurysms?

Currently, there are no drugs to treat abdominal aortic aneurysms (AAA) outside those indicated as secondary prevention drugs.  

El tratamiento endovascular parece superior a la cirugía en aneurismas rotosWhat this study shows is that diabetic patients treated with metformin had lower AAA incidence than diabetic patients treated without metformin, and even lower incidence than non- diabetic patients, as if metformin per se were a protective factor beyond diabetes. This undoubtedly calls for randomized studies with small AAA and evolution follow up.

 

The present observational and prospective study carried out in Australia included asymptomatic patients with unrepaired AAA of any diameter over 30 mm.


Read also: Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference.


Primary end point was the need to repair AAA or AAA related mortality. The association between metformin and AAA related events was assessed using Kaplan Meier analysis and Cox proportional hazard analysis.

 

It included 1080 patients with an initial average diameter of 46.1 mm, followed up for mean 2.5 years.

 

Patients with a diabetes diagnosis in treatment with metformin presented lower AAA related events than non-diabetic patients (adjusted HR 0.63, CI 95% 0.44 to 0.93), while diabetics without metformin did not (adjusted HR 1.15, CI 95% CI 0.83 to 1.59).


Read also: Risk of Colonic Ischemia after Abdominal Aortic Aneurysm Repair.


Findings were similar when looking at patients with ≤50 mm initial diameters.

 

Conclusion

These findings set grounds for a future randomized study to determine the clinical importance of metformin in AAA patients, regardless diameter or the presence or absence of diabetes.

 

Original title: Metformin Prescription is Associated with a Reduction in the Combined Incidence of Surgical Repair and Rupture Related Mortality in Patients with Abdominal Aortic Aneurysm.

Reference: Jonathan Golledge et al. Eur J Vasc Endovasc Surg. 2019 Jan;57(1):94-101.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

A New Asymptomatic Carotid Stenosis Paradigm? CREST-2 Trial Unified Results

Severe asymptomatic carotid stenosis continues to be controversial seeing the optimization of intensive medical therapy (IMT) and the availability lower periprocedural risk revascularization techniques....

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

Hypertriglyceridemia as Key Factor to Abdominal Aortic Aneurysm Development and Rupture: Genetic and Experimental Evidence

Abdominal aortic aneurysm (AAA) is a deadly vascular disease with no effective drug treatment, and risk of rupture reaching up to 80%. Even though...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...